Peptron Inc Total Liabilities

Latest as of June 2026: ₩38.50 Billion KRW ≈ $26.09 Million USD

Peptron Inc total liabilities. Based on the latest financial reports, Peptron Inc (087010) has total liabilities worth ₩38.50 Billion KRW (≈ $26.09 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Peptron Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Peptron Inc (2014–2025)

Total liabilities of Peptron Inc from 2014 to 2025. This chart illustrates how Peptron Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Peptron Inc to see how much of total assets are deployed in long-term investments.

Peptron Inc Competitors by Total Liabilities

The table below lists competitors of Peptron Inc ranked by their total liabilities.

Company Country Total Liabilities
MAP Aktif Adiperkasa Tbk PT
JK:MAPA
Indonesia Rp4.94 Trillion
KPC Pharmaceuticals Inc
SHG:600422
China CN¥4.54 Billion
PNC Process Systems Co Ltd
SHG:603690
China CN¥9.60 Billion
Econergy Renewable Energy Ltd
TA:ECNR
Israel ILA666.39 Million
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
China CN¥6.70 Billion
Oric Pharmaceuticals Inc
NASDAQ:ORIC
USA $23.43 Million
Life Healthcare
JSE:LHC
South Africa ZAC11.49 Billion
INVENTIVA ADS/1 O.N.
F:6IVA
Germany €278.03 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Peptron Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 087010 current and non-current assets.

Liquidity & Leverage Metrics

Peptron Inc Total Liabilities Ratios Explained

Peptron Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 9.11 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Peptron Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Peptron Inc (2014–2025)

The table below shows the annual total liabilities of Peptron Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩36.97 Billion
≈ $25.05 Million
+115.15%
2024-12-31 ₩17.18 Billion
≈ $11.65 Million
+4.98%
2023-12-31 ₩16.37 Billion
≈ $11.09 Million
+7.94%
2022-12-31 ₩15.17 Billion
≈ $10.28 Million
-2.70%
2021-12-31 ₩15.59 Billion
≈ $10.56 Million
-61.58%
2020-12-31 ₩40.57 Billion
≈ $27.49 Million
+23.31%
2019-12-31 ₩32.90 Billion
≈ $22.30 Million
+23.40%
2018-12-31 ₩26.66 Billion
≈ $18.07 Million
+549.70%
2017-12-31 ₩4.10 Billion
≈ $2.78 Million
-12.56%
2016-12-31 ₩4.69 Billion
≈ $3.18 Million
+5.96%
2015-12-31 ₩4.43 Billion
≈ $3.00 Million
+0.77%
2014-12-31 ₩4.39 Billion
≈ $2.98 Million
--

About Peptron Inc

KQ:087010 Korea Biotechnology & Medical Research
Market Cap
$958.68 Million
₩1.41 Trillion KRW
Market Cap Rank
#8734 Global
#224 in Korea
Share Price
₩92300.00
Change (1 day)
-5.04%
52-Week Range
₩82900.00 - ₩386000.00
All Time High
₩386000.00
About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more